Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma
Signet Ring Cell Gastric Adenocarcinoma
PROCEDURE: peri-operative chemotherapy|PROCEDURE: Surgery first
Percentage of patients dead in the 2-years, 2 years
Disease-free survival at 2 years, 2 years|Disease-free survival at 3 years, 3 years|Overall survival at 3 years, 3 years|R0 resection rate, within 1 year|grade III/IV toxicity, tolerance will be measured by the rate and grade of chemotherapy's complications, 2 years|post operative morbi-mortality, 2 years|Average of patients who benefit from the overall treatment strategy, 2 years|quality of life, 2 years|emotional status, It will be assessed by quality of life questionnaire(QLQ-C30, QLQ-STO-22,SF-36) and emotional status questionnaire(CES-D, STAI-Y-A, Brief-IPQ, WCC, ICEC-R, CRA), 2 years
The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma